Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4423-4432

  Merzouki, Abderrazzak ^a   Buschmann, Michael D ^a   Jean, Myriam ^a   Young, Rebecca S ^b   Liao, Si ^b   Gal, Susannah ^b   Li, Zuomei ^c   Slilaty, Steve N ^c  

^a ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

^b BINGHAMTON UNIVERSITY   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Adva 27a; Cancer; Multidrug efflux transporters; Multidrug resistant; Topoisomerase II

Indexed keywords

ADVA 27A; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GYRASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PODOPHYLLOTOXIN DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SENSITIVITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; MALE; MEAN RESIDENCE TIME; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; FLUORINE COMPOUNDS; HUMANS; MALE; MICROSOMES, LIVER; MONOSACCHARIDES; PODOPHYLLOTOXIN; RATS; RATS, SPRAGUE-DAWLEY; SMALL CELL LUNG CARCINOMA; TOPOISOMERASE II INHIBITORS;

EID: 84867825159     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Arnold AM: Podophyllotoxin derivative VP 16-213. Cancer Chemother Pharmacol 3: 71-80, 1979.
2. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK and Chabner B: Clinical Reversal of Multidrug Resistance. Oncologist 1: 269-275, 1996. (Pubitemid 126669388)
3. Bender RP, Jablonksy MJ, Shadid M, Romaine I, Dunlap N, Anklin C, Graves DE, and Osheroff N: Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. Biochemistry 47: 4501-4509, 2008. (Pubitemid 351522100)
4. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP and Sehested M: Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
5. Brown HS, Griffin M and Houston JB: Evaluation of cryopreserved human hepatocytes as an alternative in vitrosystem to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35: 293-301, 2007. (Pubitemid 46148743)
6. Calcagno AM and Ambudkar SV: Molecular mechanisms of drug resistance in single-step and multi-step drug-selected cancer cells. Methods Mol Biol 596: 77-93, 2010.
7. Chen Y, Su YH, Wang CH, Wu JM, Chen JC and Tseng SH: Induction of apoptosis and cell cycle arrest in glioma cells by GL331 (a topoisomerase II inhibitor). Anticancer Res 25: 4203-4208, 2005. (Pubitemid 41665205)
8. Clark PI and Slevin ML: The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12: 223-252, 1987. (Pubitemid 17072058)
9. Cole SP, Chanda ER, Dicke FP, Gerlach JH and Mirski SE: Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345-3352, 1991.
10. Giuliano C, Jairaj M, Zafiu CM and Laufer R: Direct determination of unbound intrinsic drug clearance in the microsomal stability assay. Drug Metab Dispos 33: 1319-1324, 2005. (Pubitemid 41196974)
11. Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21: 70-83, 2008.
12. Guo A, Marinaro W, Hu P and Sinko PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 30: 457-463, 2002. (Pubitemid 34263832)
13. Hande KR: Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34: 1514-1521, 1998.
14. Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC and Whang-Peng J: A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res 16: 997-1002, 1999. (Pubitemid 29368144)
15. Lee KH: Novel antitumor agents from higher plants. Med Res Rev 19: 569-596, 1999.
16. Lin S, Huang HC, Chen LL, Lee CC and Huang TS: GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription. Mol Pharmacol 60: 768-775, 2001. (Pubitemid 32900259)
17. Liu JM, Chen LT, Chao Y, Li AF, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C and Whang-Peng J: Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol 49: 425-428, 2002. (Pubitemid 34439345)
18. Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF and Batra SK: Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. Int J Cancer 120: 160-169, 2007. (Pubitemid 44901931)
19. Mirski SE, Gerlach JH, and Cole SP: Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594-2598, 1987. (Pubitemid 17083146)
20. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60:2805-2809, 2000. (Pubitemid 30395796)
21. Pitts SL, Jablonksy MJ, Duca M, Dauzonne D, Monneret C, Arimondo PB, Anklin C, Graves DE and Osheroff N: Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIalpha: potential interactions with DNA in the ternary enzyme - drug - DNA complex. Biochemistry 50:5058-5066, 2011.
22. Relling MV, Evans R, Dass C, Desiderio DM and Nemec J: Human cytochrome P450 metabolism of teniposide and etoposide. J Pharmacol Exp Ther 261: 491-496, 1992.
23. Ross W, Rowe T, Glisson B, Yalowich J and Liu L: Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857-5860, 1984. (Pubitemid 15183602)
24. Rostami-Hodjegan A and Tucker GT: Simulation and prediction of in vivo drug metabolism in human populations from in vitrodata. Nat Rev Drug Discov 6: 140-148, 2007. (Pubitemid 46745341)
25. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S and Konishi N: c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 55: 265-280, 2003. (Pubitemid 36618185)
26. Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T and Yamada Y: Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56: 2809-2814, 1996. (Pubitemid 26176695)
27. Watanabe Y, Nakajima M, Ohashi N, Kume T and Yokoi T: Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 31: 589-595, 2003. (Pubitemid 36444168)
28. Wind NS and Holen I: Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011: 967419, 2011.
29. Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW and Chan NL: Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333: 459-462, 2011.
30. Yeh GC, Lopaczynska J, Poore CM and Phang JM: A new functional role for P-glycoprotein: efflux pump for benzo(alpha) pyrene in human breast cancer MCF-7 cells. Cancer Res 52:6692-6695, 1992.
31. You Y: Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. Curr Pharm Des 11: 1695-1717, 2005.